They reduce heart rate, improve diastolic function of the myocardium, reduce secretion of renin and restore the sensitivity of β-adrenoreceptors to its regulatory influences. One of the drugs of this group is Carvedilol. It is a non-selective β and α-1-adrenoblocker. Besides β-blocking effects, it possesses vasodilatory effect without reflex tachycardia owing to blockade of α-1-adrenoblocker of peripheral vessels. 8 In a number of researches it has been shown, that treatment with Carvedilol leads to increase in stroke volume and ejection fraction of left ventricle in patients with CHF. 9, 10 It is known, that CHF is characterized by a condition of "oxidative stress". 11, 12 The condition "oxidative stress" is characterized by increase of level of lipid peroxidation (LPO) products and decrease of antioxidants that have a damaging effect on cardiomyocytes. Cardioprotective effect of carvedilol also involves direct removal of free radicals from cardiomyocytes. 13 For this reason, study of the influence of the 3 rd generation beta-adrenoblocker -carvedilol in patients with CHF-including clinical efficacy and reduction of oxidative stress is of interest.
Purpose of the study-1) To estimate clinical efficacy of long-term therapy with carvedilol in patients with chronic heart failure NYHA class III-IV due to ischemic heart disease (IHD). 2) To study influence of Carvedilol on lipidperoxidation system, structural-functional parameters of heart and autonomic nervous system regulation of heart. Study population-37 patients (33 male and 4 female) with CHF class III or IV despite receiving standard therapy of heart failure were enrolled in the study for the treatment with carvedilol. Left ventricular ejection fraction (EF) was less than 40% (by Simpson method) and no history of treatment with beta-blockers during last 2 months. Patients were excluded from the study if any of the following was present: history of MI or unstable angina within last 6 months, uncontrolled hypertension, diabetes mellitus and rheumatic heart disease.
Methodology -The study was conducted in SaintPetersburg State Medical University, from January 2000 to June 2000. It was a open-label study. All of the patients received Carvedilol for 6 months at a dose of 12.5-50mg/day with standard therapy of Heart Failure. Clinical parameters of the patients like -symptomatic improvement of shortness of breath, angina, fatigue, frequency of hospitalization, functional class of patients, crepitation in lung fields, oedema, hepatic enlargement, pulse and blood pressure were evaluated before and after the study period. Effort tolerance was evaluated by 6-minute walk test before and after carvedilol treatment. Structural and functional parameters of heart were estimated by 2D, M-mode and Doppler study on the Echo machine "Vingmed CFM-800" (Norway). Estimation of the autonomic nervous system regulation of the heart was done by determining the heart rate variability on the machine Rhythmon (Biosignal, Saint-Petersburg) at rest in standard condition. Determination of the indices of lipid peroxidation activity: the level of the plasma malondialdehyde (MDA) and superoxidedismutase (SOD) activity was investigated by spectrophotometric method.
Statistical analysis-All data analyses were carried out using statistical program "Statistica" ver.5.5A presented as M±m. The differences between the two treatment groups with p<0.5 were considered statistically significant and was estimated by Mann-Whitney, Fisher, Wilcoxon tests. Correlation analyses were carried out by Spirmen and presented as coefficientr.
Results:
The average age of the patients was 56.8±2.3 years. The cause of CHF was IHD. 34 patients had chronic stable angina (CCS class II-IV). The majority of the patients had a history of myocardial infarction (91.8%); of these 73.5% of the patients had a history of repeated MI. Hypertension was associated in 32.4% patients.
Long-term therapy with carvedilol led to improvement of the clinical status of the patients. After 6 months therapy with carvedilol frequency of hospitalization for 6 months was significantly reduced (1.36±0.23 vs. 0.33±0.1; p<0.01). The patients were symptomatically improved after 6 months therapy with carvedilol. The clinical feature after therapy with carvedilol in patients with CHF class III-IV improved to class II-III. Average functional class of heart failure reduced from 3.33±0.09 to 2.33±0.1 (p<0.01). The effort tolerance was increased with reduced shortness of breath during their performance in 54.5% patients (p<0.001). Ankle oedema and crepitation over lung fields decreased in 100% patients (p<0.001). There was reduction in feeling of fatigue in 43.4% (p<0.001) and tachycardia in 34.1% patients (p<0.001). There was a reduction in liver size in 69.7% patients (p<0.001). Frequency and duration of anginal attack decreased in 79.3% cases.
The heart rate in patients treated with carvedilol was significantly reduced but there was no bradycardia (83.7±1.8/min vs. 67.3±1.5/min, p<0.001). Data on chest x-ray showed a significant reduction in signs of pulmonary congestion in 100% patients. Significant increase in the distance traversed by the patients during a 6 minutes walk was observed in patients after 6 months therapy with carvedilol (342.9±22.5 meter vs. 411.6±15.0 meter, p<0.001).
Left ventricular hypertrophy (LVH) was diagnosed in all patients with CHF class III-IV by echocardiographic criteria. The average value of the index of left ventricular mass before therapy was 214.0±11.1 gm/m 2 . After therapy with carvedilol, there was a tendency of reduction of this parameter by 12.1% (214.0±11.1 gm/m 2 vs. 188.1±10.8 gm/m2, p<0.05). After treatment with carvedilol there was significant increase in LVEF by 10% (30.0±1.5% to 33.0±0.1%; p<0.01) and increase in fractional shortening of LV by 22.2% (from 17.25±1.14 to 21.09±1.25; p<0.01). Significant reduction in LV systolic volume by 5.1% was observed (5.66±0.19 cm vs. 5.37±0.19 cm; p<0.05). In patients with CHF class III-IV the parameters of LV diastolic function were not changed significantly.
Table-I Clinical parameters of patients with CHF FC III & IV before and after therapy with Carvedilol.

Clinical parameters
Before therapy (n =33) After Therapy (n = 33) 
Discussion:
CHF is an evolving problem of contemporary cardiology as being a final pathway of practically all cardiovascular diseases and one of the leading causes of mortality.
For last few years, the pathophysiology of CHF has been explored. Now the great importance has been given to neurohumoral changes participating in regulation of blood circulation. 14, 15 The most important neurohormonal change is the changes of Sympathetic Nervous System along with renin angiotension aldosteron system. 16, 17 It is known that CHF is accompanied by development of oxidative stress. 18, 19, 20 It can aggravate contractile dysfunction of myocardium that promotes further progression of CHF. For this reason, search of preparations for effective and optimum treatment, which can reduce oxidative stress in CHF, is important and requires further study. 21, 22 Inclusion of β-adrenoblocker in treatment of CHF is a new concept. 5, 9, 15 Carvedilol is non-selective β -and simultaneously α1-adrenoblocker. Besides its modulating influence on SNS, it also possesses cardioprotective effect by its antioxidant properties. Carvedilol and its metabolites promote removal of free radicals from cells and suppress oxidation of LDL, interfere with formation of cytotoxic and highly atherogenic forms of lipoproteins. 13 In this study, the clinical efficacy of long-term (6 months) treatment with carvedilol (12.5-50 mg/ day) in patients with CHF, its influence on structural-functional parameters of myocardium and the autonomic nervous system regulation of heart rate was studied. Also effect of carvedilol on lipid peroxidation (LPO) was evaluated in this group of patients.
Long-term treatment with carvedilol promoted improvement of effort tolerance with reduction of effort dyspnea in 54.5% patients, reduction in frequency and duration of episodes of anginal attacks. Heart rate was significantly decreased by 19.6 %. There was a significant reduction in NYHA functional class of CHF. Distinct clinical efficacy of carvedilol in patients with CHF with the above described changes have also been demonstrated in works of other authors. 6, 9, 10, [23] [24] [25] [26] [27] [28] In the US Carvedilol Heart Failure Trials Program, (1996), 29 patients with CHF were treated with placebo or carvedilol in doses up to 25-50 mg/ day for 6-12 months. Treatment with carvedilol improved the clinical symptoms and produced a significant improvement in NYHA functional class. S.L.Olsen et. al. also showed treatment of CHF with carvedilol led to significant reduction in heart rate and functional class of CHF. 10 However, in ANZ-study, in patients with CHF I-III FC treatment with carvedilol in doses 25-50 mg/day during 6-12 months, improvements of clinical symptoms were not observed . 30, 31 In 65% of the surveyed patients the clinical condition, didn't change, in 23% of patients there was clinical improvement and in 12% -deterioration of clinical symptoms of CHF was observed. In this study, the structure of the group of patients could affect the results, where 59% patients were with CHF NYHA Functional Class-II, 30 % with Functional Class-I and 11% with Functional Class-III made 59%.
An estimation of effort tolerance in patients with CHF the 6-minute walk test is widely used. It is especially convenient for an estimation of effort tolerance in patients with severe symptoms of disease, especially when opportunities of application of other objective methods are limited. 32 -34 There is significant increase in distance passed by patients for 6 minutes after 6 months of treatment with carvedilol has been established in comparison with the baseline data by 20.0% (from 342.9 ±22.47 m up to 411.6±15.04 m, p < 0.001). According to the data of some authors, on a background of therapy with carvedilol, there was marked increase in walking distance of patients for 6 minutes in comparison with a baseline level. 9, 35 In other works, there was no marked influence of carvedilol on the given parameter. 36, 37 The reasons of these disagreements, probably, are related to carrying out of the test in conditions of single or multicentre trials. Positive results of the given test have been received in single-centre studies where there was also observed significant improvement of quality of life of the patients. In multicentre studies there were no marked changes of this parameter. Probably, the test with 6-minute walking is reliable, when are used in conditions of single center where the patient and the researcher are more motivated for receiving of the best results.
Clinical
Spectral analysis of heart rate variability now is considered as one of the most sensitive noninvasive methods of an estimation of autonomic nervous system regulation of heart. The numerous data shows that in patients with CHF there is significant -steady reduction in the total heart rate variability. 38, 39 It is a parameter of imbalance of autonomic nervous system, where activity of SNS dominates and parasympathetic activation is reduced. [40] [41] [42] [43] [44] [45] In this study, in patients with CHF III-IV FC on a background of therapy with carvedilol, significant increase in parameters of HF component of the spectrum of heart rate variability by 290.6% was observed; but the power of LF component practically did not change in absolute as well as in relative units. It is the reflection of modulating influence of carvedilol on autonomic nervous system.
Analyzing the parameters of LV systolic function estimated by echocardiography, it is necessary to note that after 6-months therapy with carvedilol there was significant increase in LVEF (by 10%), and fractional shortening (by 22.2%). There was significant reduction in the parameters of the left ventricular end systolic volume by 5.1% from the baseline data.
Long-term therapy with carvedilol was accompanied by reduction in LV myocardial mass index by 12.1% that indicates the reduction of the degree of left ventricular hypertrophy. The changes in the parameters of the autonomic nervous system control of heart, which was revealed during therapy with carvedilol, could promote reversal of the remodeling of heart in patients with CHF III-IV FC.
So, therapy with carvedilol led to improvement of the parameters reflecting the LV systolic function. The similar data have been received also by other authors. 6, 9, 10, 36 In majority of the patients with CHF the combination of systolic and diastolic dysfunctions of myocardium was observed. 46, 47 On a background of 6-months therapy with carvedilol in patients with CHF III-IV FC, the parameters of the LV diastolic function were not changed significantly, but there was some improvement of these parameters (the peak A and IVRT have increased, peak Å and E/A have decreased). The similar data are also received by other authors. [48] [49] [50] Thus; carvedilol restores the LV systolic function and promotes reduction in LV diastolic dysfunction.
The changes in the structural-functional parameters of the myocardium observed in this study indicates that carvedilol exerts positive influence on LV function not only by reducing heart rate and vasodilatation, but also due to improvement of myocardial contractility. Thus there is special value of the anti-proliferative and antioxidant actions of carvedilol on cardiomyocytes. 19, 59 It indicates the reduction of antioxidant defense system in patients with CHF in comparison with healthy persons. In the present study, in treatment with carvedilol, it has not been revealed significant changes of the plasma SOD activity.
In our study, the average values of plasma MDA level in patients with CHF in comparison with healthy people have been increased. After 6-months of therapy with carvedilol in patients with CHF class III-IV, there was a significant reduction in plasma MDA in comparison with the baseline data (14.94±0.84 mkmol/l to 12.93±1.11 mkmol/l; p>0.05). Reduction of plasma MDA level may be the consequence of direct antioxidant effect of the drug. 60 Analysis of the dose-dependant effect of carvedilol, large doses (more than 25mg/day) were associated with significant improvement in clinical symptoms and LPO state. However, even small doses (less than 25 mg/ day) led to improvement of some investigated parameters. The received results confirm the available data about dose dependant effect of carvedilol. 36, 61 At an estimation of clinical efficacy of a drug, it is necessary to take into account its tolerance and safety. Tolerance of a drug is determined by frequency of occurrence of side effects on a background of the therapy, resulting in withdrawal of the given drug. In treatment with carvedilol the most frequent side effects were hypotension and dizziness, usually observed during titration period of the drug. Probably, it is related to its vasodilatory action. Similar side effects were also reported in other studies. 6, 9 Conclusions: 1. Long-term therapy with carvedilol led to ameliorate the clinical symptoms of heart failure class III-IV which accompanied with the increased effort tolerance.
2. Long-term therapy with carvedilol in patients with CHF class III-IV increased LV ejection fraction and fractional shortening. There was improvement of the indices of LV diastolic function.
3. Therapy with carvedilol in patients with CHF class III-IV reduced level of plasma malondialdehyde without changing the plasma SOD activity.
4. Carvedilol exerts a modulating effect on the indices of the HRV in patients with CHF class III-IV.
Practical recommendations:
For treatment of the patients with ischemic heart disease and chronic heart failure class IIII-IV, in addition to the standard therapy including nitrates, ACE-inhibitors, diuretics and if necessary -cardiac glycosides carvedilol may be recommended for its high clinical efficacy and safety.
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